AA
CMPX icon

ALPS Advisors’s Compass Therapeutics CMPX Stock Holding History

ALPS Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400K Buy
182,777
+36,170
+25% +$107K ﹤0.01% 1048
2026
Q1 		$776K Buy
146,607
+567
+0.4% +$3.27K ﹤0.01% 622
2025
Q4 		$784K Buy
146,040
+63,033
+76% +$291K ﹤0.01% 629
2025
Q3 		$291K Buy
83,007
+8,410
+11% +$26.6K ﹤0.01% 994
2025
Q2 		$194K Buy
+74,597
New +$154K ﹤0.01% 1008
2023
Q4 		– Sell
-94,115
Closed -$185K – 973
2023
Q3 		$185K Buy
94,115
+1,127
+1% +$2.79K ﹤0.01% 958
2023
Q2 		$296K Buy
+92,988
New +$292K ﹤0.01% 884

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ALPS Advisors's CMPX Position: Q2 2026 in Review

ALPS Advisors increased its Compass Therapeutics (CMPX) stake by 25% in Q2 2026, buying an estimated $107K and bringing the position to 182,777 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #1048.

ALPS Advisors first reported a position in CMPX in Q2 2023 and has held it in 7 quarters since. The position peaked at $784K in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • ALPS Advisors held 182,777 shares of Compass Therapeutics worth $400K as of Q2 2026.
  • ALPS Advisors bought 36,170 Compass Therapeutics shares in Q2 2026, an estimated $107K.
  • Compass Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1048 holding.
  • ALPS Advisors first reported a position in Compass Therapeutics in Q2 2023 and has held it in 7 quarters since.
  • ALPS Advisors's Compass Therapeutics position peaked at $784K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.